CRMP-3 Polyclonal Antibody
Sizes: 50μL, 100μL
Catalogue Numbers: RA23811-50, RA23811-100
Citations, Manuals and MSDS Available upon request.
Background: disease:Antibodies against post-translationally modified DPYSL4, also called anti-CV2 autoantibodies, are present in sera from patients with paraneoplastic neurological diseases (PND) . PND are disorders of the nervous system associated with various systemic cancers which are not a direct result of the tumor mass or metastasis, but attributed to remote effects of the cancer.,function:Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance, neuronal growth cone collapse and cell migration.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,similarity:Belongs to the DHOase family. Hydantoinase/dihydropyrimidinase subfamily.,subunit:Homotetramer, and heterotetramer with CRMP1, DPYSL2, DPYSL3 or DPYSL5. Interacts with PLEXA1.,
Condition: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage Instructions: -20°C/1 year
Recommended dilutions: Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.
Alternative Names: DPYSL4; CRMP3; ULIP4; Dihydropyrimidinase-related protein 4; DRP-4; Collapsin response mediator protein 3; CRMP-3; UNC33-like phosphoprotein 4; ULIP-4
Applications: WB; ELISA
Species Cross-Reactivity: Human; Mouse; Rat
GeneID (Human): 10570
Protein MW (KDa): 62
SWISS: O14531
Source: Rabbit
Research Use Only